A Mukherjee1, V G Hale, O Borga, R Stein. 1. Division of Anti-inflammatory, Analgesic and Ophthalmologic Drug Products, Food and Drug Administration, Rockville, MD 20857, USA.
Abstract
OBJECTIVE AND DESIGN: Relevance of the preclinical pharmacodynamic, toxicity and pharmacokinetic parameters predicting the clinical potency of nonsteroidal antiinflammatory drugs (NSAIDs) was evaluated. MATERIAL: Data for oral potencies of 24 NSAIDs in rats were collected from the literature and from New Drug Applications with respect to the following parameters: antiinflammatory, analgesic, antipyretic, acute ulcerogenic activities, acute toxicity, in vitro inhibition of prostaglandin synthesis, acid dissociation constant (pKa), octanol-water partition coefficient and elimination half-life. TREATMENT: Data for most of the in vivo parameters in rats were collected following single dose administration with the exception of adjuvant arthritis. Single and daily clinical doses were considered. All of these NSAIDs have been approved for marketing although not all have been sold in the USA. METHODS: The preclinical data were compared to human dose (unit or daily doses) using single and multiple stepwise regression analyses. RESULTS: Analyses suggest that NSAIDs are effective in all models of preclinical tests for fever, pain and inflammation, however, carrageenin-induced rat paw edema model is clearly the best predictor of human dose. Rank order of preclinical models for predicting human dose is carrageenin > yeast induced fever > pressure induced pain = adjuvant arthritis in rats. The analysis suggested that the pain and adjuvant arthritis models in rats may also involve a prostaglandin independent mechanism. Of the two physicochemical factors tested, pKa contributed best to the carrageenin model towards predicting the clinical potency of NSAIDs. Mathematical relationships between human dose, carrageenin ED50 and pKa were established that may assist in the future clinical development of NSAIDs. CONCLUSIONS: Carrageenin-induced paw edema model in rats is the most robust predictor of the clinical potency of NSAIDs. Acid dissociation constant (pKa) appears to be a secondary contributor to the potency of NSAIDs. The relevance of the data analyses for developing cyclooxygenase-2 (COX-2) selective NSAIDs is discussed.
OBJECTIVE AND DESIGN: Relevance of the preclinical pharmacodynamic, toxicity and pharmacokinetic parameters predicting the clinical potency of nonsteroidal antiinflammatory drugs (NSAIDs) was evaluated. MATERIAL: Data for oral potencies of 24 NSAIDs in rats were collected from the literature and from New Drug Applications with respect to the following parameters: antiinflammatory, analgesic, antipyretic, acute ulcerogenic activities, acute toxicity, in vitro inhibition of prostaglandin synthesis, acid dissociation constant (pKa), octanol-water partition coefficient and elimination half-life. TREATMENT: Data for most of the in vivo parameters in rats were collected following single dose administration with the exception of adjuvant arthritis. Single and daily clinical doses were considered. All of these NSAIDs have been approved for marketing although not all have been sold in the USA. METHODS: The preclinical data were compared to human dose (unit or daily doses) using single and multiple stepwise regression analyses. RESULTS: Analyses suggest that NSAIDs are effective in all models of preclinical tests for fever, pain and inflammation, however, carrageenin-induced rat paw edema model is clearly the best predictor of human dose. Rank order of preclinical models for predicting human dose is carrageenin > yeast induced fever > pressure induced pain = adjuvant arthritis in rats. The analysis suggested that the pain and adjuvant arthritis models in rats may also involve a prostaglandin independent mechanism. Of the two physicochemical factors tested, pKa contributed best to the carrageenin model towards predicting the clinical potency of NSAIDs. Mathematical relationships between human dose, carrageenin ED50 and pKa were established that may assist in the future clinical development of NSAIDs. CONCLUSIONS:Carrageenin-induced paw edema model in rats is the most robust predictor of the clinical potency of NSAIDs. Acid dissociation constant (pKa) appears to be a secondary contributor to the potency of NSAIDs. The relevance of the data analyses for developing cyclooxygenase-2 (COX-2) selective NSAIDs is discussed.
Authors: S Higuchi; Y Osada; Y Shioiri; S Nakaike; M Muramatsu; M Tanaka; I Arai; F Amanuma; S Otomo; H Aihara Journal: Nihon Yakurigaku Zasshi Date: 1984-05
Authors: A S Kalgutkar; B C Crews; S W Rowlinson; A B Marnett; K R Kozak; R P Remmel; L J Marnett Journal: Proc Natl Acad Sci U S A Date: 2000-01-18 Impact factor: 11.205
Authors: Elke H J Krekels; Marie Angesjö; Ingemo Sjögren; Kristina Angeby Möller; Odd-Geir Berge; Sandra A G Visser Journal: Pharm Res Date: 2011-02-23 Impact factor: 4.200
Authors: Ronald Esser; Carol Berry; Zhengming Du; Janet Dawson; Alyson Fox; Roger A Fujimoto; William Haston; Earl F Kimble; Julie Koehler; Jane Peppard; Elizabeth Quadros; Joseph Quintavalla; Karen Toscano; Laszlo Urban; John van Duzer; Xiaoli Zhang; Siyuan Zhou; Paul J Marshall Journal: Br J Pharmacol Date: 2005-02 Impact factor: 8.739
Authors: Ana C Puhl; Flora A Milton; Aleksandra Cvoro; Douglas H Sieglaff; Jéssica C L Campos; Amanda Bernardes; Carly S Filgueira; Jan Lammel Lindemann; Tuo Deng; Francisco A R Neves; Igor Polikarpov; Paul Webb Journal: Nucl Recept Signal Date: 2015-10-05